All publications

Export 169 results:
Author Title Type [ Year(Desc)]
2011
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT.  2011.  Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.
2012
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A.  2012.  Automated Analysis of A1 cluster dynamics in the UK 2007-2010. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Bulteel N, Nelson M, Churchill D, Sabin CA.  2012.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort. 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2012.  Estimating the heritability of viral determination of progression rate. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn DT.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn DT.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Williams I, Geretti AM, Mackie N, Pillay D, Dunn DT et al..  2012.  Has a Limit to the Decline in Transmitted Drug Resistance Been Reached? Evidence from a Large Surveillance Study of UK-acquired Infections 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Bradshaw D, Dolling D, Booth C, Nelson M, Dunn DT, Asboe D.  2012.  How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Castro H, Dunn DT, Cane P A, Asboe D, Cambiano V, Phillips AN, Pillay D, UK HIV Drug Resistance Database.  2012.  Persistence of transmitted HIV drug resistance mutations. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A167.
Sethi G, Sabin CA, Lycett S, Ragonnet-Cronin M, Edwards SG, Fearnhill E, Dunn DT, Delpech V, Phillips AN, Pillay D et al..  2012.  Phylogenetic analysis of HIV transmission among different ethnic MSM groups in the UK. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2012.  Population based study indicates viral genetic effect on HIV virulence is small but significant. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Donegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.
Koning FA, Castro H, Dunn DT, Mbisa JL, Cane P A, UK HIV Drug Resistance Database.  2012.  Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2012.  Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
2013
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A, UK Collaborative Group on HIV Drug Resistance.  2013.  Dynamics of Non-B HIV Transmission in the UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.